

**Consolidated Financial Results for FY2018**

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2017		FY2018		YoY
	Apr. 2017-Mar. 2018		Apr. 2018-Mar. 2019		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	48,944	100.0%	46,706	100.0%	-4.6%
Cost of Sales	30,059	61.4%	27,814	59.6%	-7.5%
Gross Profit	18,884	38.6%	18,891	40.4%	0.0%
Selling, General and Administrative Expenses	16,060	32.8%	17,107	36.6%	6.5%
Operating Income	2,824	5.8%	1,782	3.8%	-36.9%
Profit Attributable to Owners of Parent	2,388	4.9%	1,744	3.7%	-27.0%

**Forecast of Consolidated Financial Results for the FY2019**

	FY2018 Actual		FY2019 Forecast		YoY
	Apr. 2018-Mar. 2019		Apr. 2019-Mar. 2020		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	46,706	100.0%	53,000	100.0%	13.5%
Operating Income	1,782	3.8%	2,000	3.8%	12.2%
Profit Attributable to Owners of Parent	1,744	3.7%	1,000	1.9%	-42.7%

**Sales of Main Products**

(Billions of yen)

Therapeutic Category	Products	FY2017 Actual	FY2018 Actual	FY2019 Forecast
Antihypertensive agent	CANDESARTAN*	13.23	11.92	13.60
Thyroid hormone	THYRADIN	4.91	5.66	6.98
LH-RH derivative	LEUPRORELIN	4.16	4.17	4.52
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	1.06	2.48	3.89
Hyperlipidemic agent	LIPDIL	4.29	1.80	1.21
Antihypertensive agent	AMLODIPINE	1.62	1.39	1.53
Emergency contraceptive	NORLEVO	1.21	1.29	0.66
Prostate cancer therapeutic agent	BICALUTAMIDE	1.58	1.22	1.06
Dysmenorrhea agent	FREWELL	-	0.67	2.01
GnRH antagonist	RELUMINA	-	0.36	1.98

\*Including CANDESARTAN formulation's sales